Development of New Immunotherapies for Japanese Cedar Pollinosis

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)


Volume 16, 3 Issues, 2017


Download PDF Flyer




Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Claudiu T. Supuran
Neurofarba Department
University of Florence
Florence
Italy


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Development of New Immunotherapies for Japanese Cedar Pollinosis



Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 4(2): 193-198.

Author(s): Masahiro Sakaguchi and Kazuki Hirahara.

Affiliation: Laboratory for Allergy Regulation, Research Center for Allergy and Immunology, RIKEN (The Institute of Physical and Chemical Research), 1-7-22 Suehiro-cho, Tsurumiku, Yokohama, Kanagawa, 230-0045 Japan.

Abstract

We developed new immunotherapies (peptide and DNA vaccines) for treatment of Japanese cedar pollinosis. In the first place, oral administration of a dominant T cell epitope of a major Japanese cedar allergen (Cry j 2) in mice induced immunologic tolerance in both T-helper (Th) 1 and Th2 cell responses against the whole protein allergen. We found that peptide-based oral immunotherapy has a potential efficacy for treatment of the allergic immune response. Further, we developed a hybrid peptide comprising 7 T cell epitopes for human patients. It is expected that the hybrid peptide will downregulate allergen-specific T cells. We are planning a clinical study with the hybrid peptide in the near future. In the second place, we evaluated the use of DNA immunization by inoculating mice with plasmid DNA encoding a major Japanese cedar allergen (Cry j 1) gene. This DNA vaccination suppressed the IgE and IgG1 responses to subsequent alum-precipitated Cry j 1 injections. These results suggest that the DNA vaccination effectively induced Cry j 1-specific Th1-type immune responses, resulting in inhibition of the IgE responses to Cry j 1. Further, we developed DNA vaccine encoding both T cell epitope in Cry j 2 and invariant chain for the delivery of the epitope peptide into major histocompatibility complex (MHC) class II loading pathway. This DNA vaccination also suppressed the IgE responses to subsequent alum-precipitated Cry j 2 injections. DNA vaccine encoding T cell epitope and invariant chain induced epitope-specific T cell responses without allergic side effects.

Keywords:

immunotherapy, allergies, allergen-specific therapy, cryptomeria japonica, peptide vaccine, allergen gene, epitopes.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 4
Issue Number: 2
First Page: 193
Last Page: 198
Page Count: 6
DOI: 10.2174/1568014053507041
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science